A prospective, multicentre, open-label, randomised, phase 2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU), or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line therapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma

Trial Profile

A prospective, multicentre, open-label, randomised, phase 2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU), or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line therapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Masitinib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 16 Sep 2015 Results published in an AB Sciences media release.
    • 16 Sep 2015 According to an AB Sciences media release, the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug designation for masitinib in the treatment of esophagogastric adenocarcinoma.
    • 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top